Centre Hospitalier General

The trials here

What the 12 trials at this site are about, from their registry records.

Conditions

• Multiple sclerosis10 trials
• Stroke2 trials
• Coronary artery disease1 trial

Phase

• Phase 312 trials

Status

• Recruiting5 trials
• Active, not recruiting3 trials
• Completed3 trials
• Not yet recruiting1 trial

Lead sponsor

• Novartis Pharmaceuticals2 trials
• Sanofi2 trials
• Assistance Publique - Hôpitaux de Paris1 trial
• Fondation A De Rothschild1 trial
• Hoffmann-La Roche1 trial
• and 5 more

Running trials

• Not yet recruiting

  Tenecteplase for the treatment of acute stroke in the late time window before inter-hospital transfer for thrombectomy: a randomized controlled trial

  2026-525280-40-00· Phase 3· Fondation A De Rothschild· Source

• Recruiting

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis

  NCT07067463· Phase 3· Zenas BioPharma (USA), LLC· Source

• Not yet recruiting

  Disease Modifying Therapies Withdrawal in Inactive Relapsing-remitting Multiple Sclerosis Patients Aged 55 and Over (TWINS : Therapies Withdrawal IN Relapsing Multiple Sclerosis)

  NCT06663189· Phase 3· University Hospital, Strasbourg, France· Source

• Active, not recruiting

  Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis

  NCT06141486· Phase 3· Sanofi· Source

• Recruiting

  For patients with active multiple sclerosis, impact of annual versus semi-annual infusions of ocrelizumab after 2 years of initial treatment on the absence of radiological disease activity at 2 years: a multicentre randomised controlled non-inferiority trial

  2023-505420-62-00· Phase 3· Hopital Fondation Adolphe De Rothschild· Source

• Recruiting

  RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis.

  NCT05758831· Phase 3· Rennes University Hospital· Source

• Recruiting

  Evaluation of Low Dose Colchicine and Ticagrelor in Prevention of Ischemic Stroke in Patients With Stroke Due to Atherosclerosis

  NCT05476991· Phase 3· Assistance Publique - Hôpitaux de Paris· Source

• Active, not recruiting

  Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)

  NCT05156281· Phase 3· Novartis Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Multiple sclerosis4 recruiting
• Stroke2 recruiting
• Coronary artery disease1 recruiting

Closed trials

• Completed

  Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS

  NCT04788615· Phase 3· Novartis Pharmaceuticals· Source

• Completed

  Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

  NCT04458051· Phase 3· Sanofi· Source

• Completed

  This is an Extension Study of the Roche P-trials to Investigate Safety and Effectiveness of Ocrelizumab in Participants With Multiple Sclerosis (MS)

  NCT03599245· Phase 3· Hoffmann-La Roche· Source